Therapeutic Drug Monitoring
Breakthrough technology for monitoring biotherapies
Monoclonal antibodies offer unprecedent opportunity to drug development with remarkable efficacy and safety and have significantly improved the prognosis of more than 14 millions patients with newdeclared cancers and patients currently living with chronic inflammatory disease.
These novel drugs can be used either as a monotherapy or in combination, reinforcing the therapeutic Armamentarium of the clinicians. In these contexts, therapeutic monitoring of biotherapy has become a new preoccupation for clinicians.
It consists in monitoring the clearance of a monoclonal antibody, injected alone or in combination, in the serum of a patient. Thus, monitoring of biotherapies allows: